20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW. WHO.INT
Ref.: C.L.20.2021
The World Health Organization (WHO) presents its compliments to Member States and
Associate Members and has the pleasure of announcing that the 44th Expert Committee on Drug
Dependence (ECDD) will meet from 11 to 15 October 2021, coordinated from Geneva,
Switzerland. Given that WHO Expert Committee meetings are of a closed nature, this letter
serves to notify Member States of the substances under review at the 44th ECDD, which are in
… the Annex I, attached for reference.
WHO is mandated by the 1961 and 1971 International Drug Control Conventions to make
recommendations to the UN Secretary-General on the need for and level of international control
of psychoactive substances based on the advice of its independent scientific advisory body, the
ECDD. To assess the appropriate control of a psychoactive substance, the ECDD convenes
annually to review the potential of this substance to cause dependence, abuse and harm to health,
as well as any therapeutic applications. In order to perform this review and make scientific and
evidence-based decisions, the ECDD conducts medical, scientific, and public health evaluations
of the selected psychoactive substances using the best available information.
Although the meetings are of a closed nature, Member States are invited to contribute to
the ECDD review process by joining the 44th ECDD Information Session on 11 October 2021.
The Information Session will allow interested parties to learn about present and future activities
of the ECDD Secretariat, and to present information concerning substances under review to the
Expert Committee. Registration information will be made available on the ECDD web site in due
course: https://www.who.int/medicines/access/controlled-substances/en/.
As in the past and in line with the publication “Guidance on the WHO review of
psychoactive substances for international control” (EB126/2010/REC1, Annex 6) 1, Member
States can also contribute to the ECDD review process by providing up to date and accurate
information concerning the substances under review in advance of the meeting. For this purpose,
and as per previous practice, a questionnaire will be sent to Member States to gather country
information on the legitimate use, harmful use, status of national control and potential impact of
international control for each substance under evaluation.
… Annex II to this Circular Letter contains a list of national focal points officially designated
by Member States in previous years who provide country information to the ECDD through the
Member States questionnaire referred to above. If the focal point information requires changes or
amendments, Member States are invited to inform the WHO ECDD Secretariat by email to
1
http://apps.who.int/gb/ebwha/pdf_files/EB126-REC1/B126_REC1-en.pdf#page=58.
... ENCLS: (2)
Page 2
C.L.20.2021
[email protected] by 1 July 2021 with the subject “44ECDD Focal Point: (Country
Name)”.
If the individual on the list is still the official focal point for completing the ECDD
Member State questionnaire this year and if no additions or amendments to focal point details are
made by 1 July 2021, the focal point from the list will be given further instructions and direct
access to online questionnaires by the WHO Secretariat. Results of the questionnaires will be
prepared as a report as part of the 44th ECDD substance review process.
In addition to the questionnaire, Member States are also encouraged to provide any
additional relevant information (unpublished or published) on substances to be reviewed by the
44th ECDD by emailing
[email protected] with the subject “Ref: C.L.20.2021”.
The World Health Organization takes this opportunity to renew to Member States and
Associate Members the assurance of its highest consideration.
GENEVA, 10 June 2021
Annex I
44rd Expert Committee on Drug Dependence (ECDD)
11–15 October 2021
Substances for review
Critical reviews:
The substances listed below have never been formally reviewed by WHO and are not currently
under international control. Information was brought to WHO’s attention that these substances are
clandestinely manufactured, of especially serious risk to public health and society, and of no recognised
therapeutic use by any Party. The Expert Committee will consider whether information presented during
a critical review may justify the scheduling or a change in the scheduling of the substance in the 1961 or
1971 Conventions.
Synthetic cannabinoid receptor agonists
1. 4F-MDMB-BICA (4F-MDMB-BUTICA)
Novel synthetic opioids
2. Brorphine
3. Metonitazene
Cathinones/stimulants
4. Eutylone (bk-EBDB)
5. BMDP (3,4-Methylenedioxy-N-benzylcathinone), benzilone
Pre-reviews:
The substances listed below have been proposed for a pre-review. The purpose of a pre-review is
to determine whether current information justifies an Expert Committee critical review. A pre-review is a
preliminary analysis and findings at this stage should not determine whether the control status of a
substance should be changed.
Herbal drugs
1. Kratom, mitragynine, 7-hydroxymitragynine
Medicines
2. Phenibut
Annex 2
List of focal points designated by Member States in previous years
Country Name Focal Point E-mail Affiliation Position
Afghanistan Shahpoor Yousuf
[email protected]
Regulation Sector of Regulation Sector of
Albania Linda Ternova
[email protected] Pharmaceutical Market and Pharmaceutical Market and
Medical Devices Medical Devices
Chargé du dossier des
stupéfiants, des
Algeria Ghrieb Houria
[email protected]
psychotropes et des
précurseurs chimiques
Department of Health
Andorra Carla Lobaco Valls
[email protected] Technical officer
Resources and Medicines
Department of Health
Andorra Carme Pallarés Papaseit
[email protected] Chief
Resources and Medicines
Angola
Antigua and Barbuda
Administración Nacional de
Argentina G. Rebaldería
[email protected] Medicamentos, Alimentos y Psicotrópicos
Tecnología
Controlled Substances
Armenia Hasmik Martirosyan
[email protected] Head
Management Department
Australia Allison Jones
[email protected]
UN Health Section,
International and
Commonwealth/State
Australia Leila Jordan
[email protected] Director
Relations Branch, Australian
Government Department of
Health
Austria Raphael Bayer
[email protected]
Telman Suleyman Oglu
Azerbaijan
[email protected]
Mammadhassanov
1
Annex 2
Country Name Focal Point E-mail Affiliation Position
Bahamas
Bahrain Samar Yousef Salem
[email protected]
Addl. Secretariat, Health
Md. Habibur Rahman
Bangladesh
[email protected] Services Division, Ministry of
Khan
Health and Family Welfare
Barbados Maryam Hinds
[email protected] Barbados Drug Service
Организационно-
методический отдел,
государственное
Заведующий сектором
Belarus Инна Белаец
[email protected] учреждение
наркологии
“Республиканский научно-
практический центр
психического здоровья”
Epidemiology and public
Belgium Peter Blankaert
[email protected] Director
health
Belize
Direction de la Pharmacie, du
Benin Hope Akohouvi Amou
[email protected] Médicament et des Pharmacien Diplômé d’Etat
Explorations Diagnostiques
Bhutan Dil Kumar Subba
[email protected]
Bolivia (Plurinational State of) Maria Julia Carrasco
[email protected]
Bosnia and Herzegovina Ana Cvijanović
[email protected]
Bosnia and Herzegovina Sabina Šahman
[email protected]
Department of Clinical
Botswana Vivian Sebako
[email protected] Chief Pharmacist
Services
Maria Dilma Alves
Brazil
[email protected]
Teodoro
National Health Surveillance Controlled products
Brazil Renata de Morais Souza
[email protected]
Agency (Anvisa) manager
Brazil
[email protected]
2
Annex 2
Country Name Focal Point E-mail Affiliation Position
Director of Pharmaceutical
Brunei Darussalam Hajah Rosni Haji Jair
[email protected]
Services
Health Promotion and
Bulgaria Slaveyka Nikolova
[email protected] Prophylaxis of Diseases and Senior Expert
Addictions
National Focal Centre in the
Bulgaria
[email protected] National Centre of Narcotic Director
Addictions
Ouedraogo Soutongo Sita Agence Nationale de
Burkina Faso
[email protected] Pharmacien
Sandrine Régulation Pharmaceutique
Burundi Aimable Bizoza
[email protected]
Entidade Reguladora Director of the
Cabo Verde Lenira Centeio
[email protected] Independente da Saúde Pharmacuetical Regulation
(ERIS) Directorate
Entidade Reguladora Technician of the
Cabo Verde Cheila Barros
[email protected] Independente da Saúde Pharmaceutical Regulation
(ERIS) Directorate
Member of the Board
Entidade Reguladora
Direction of ERIS,
Cabo Verde Íris de Vasconcelos Matos
[email protected] Independente da Saúde
responsable for the
(ERIS)
pharmaceutical area
Cambodia Chhit Sophal
[email protected]
Cameroon Ketchozo Loko Wilfried
[email protected]
Canada
[email protected]
Central African Republic
Chad Haoua Haroun Saker
[email protected]
Department of Mental Health. Advisor for the Department
Chile Alejandro Riquelme
[email protected]
Ministry of Health of Chile of Mental Health
Department of Mental Health.
Chile Pablo Norambuena
[email protected] Mental Health Advisor
Ministry of Health of Chile
3
Annex 2
Country Name Focal Point E-mail Affiliation Position
Department of Mental Health. Head of the Mental Health
Chile Matias Irarrazaval
[email protected]
Ministry of Health of Chile Department
National Narcotics Deputy Director of Division
China Hua Zhendong
[email protected]
Laboratory II
Office of National Narcotics Officers from International
China Wang Wei
[email protected]
Control Commission Cooperation Division
National Narcotics
China Xu Peng
[email protected] Senior Expert
Laboratory
Colombia Oscar Ricardo Santana
[email protected]
Coordinadora del Grupo de
Convivencia Social y
Colombia
[email protected] Ministerio de Salud
Ciudadanía de la Dirección
de Promoción y Prevención
Colombia A. Peñuela
[email protected]
Comoros
Ghislaine Mbelu
Congo
[email protected]
Kanyunya
Cook Islands Valentino Wichman
[email protected]
Costa Rica Marchena Vasquez
[email protected]
Directeur Coordonnateur du
Programme National de
Côte d’Ivoire Ernest Zotoua
[email protected] Lutte contre le Tabagisme,
la Toxicomanie et les autres
Addictions
Croatia Romana Katalinić
[email protected]
Cuba
Cyprus John Kkolos
[email protected]
Czech Republic Vlastimil Brandejs
[email protected]
4
Annex 2
Country Name Focal Point E-mail Affiliation Position
Democratic People’s Republic of
Korea
Democratic Republic of the Congo
Denmark Maria Koch Aabel
[email protected]
Djibouti
Dominica
Dominican Republic Elizabeth Ruiz
[email protected]
Francisca Dalia Castillo
Dominican Republic
[email protected]
Sanchez
Internal Management of
Mental Health and Integral
Ecuador Enríquez Anaya
[email protected] Prevention of the
Socioeconomic
Phenomenon of Drugs Area
Analyst of the transition
process of the “Drugs
Ecuador Rojeab Bravo
[email protected] Technical Secretariat” into a
Ministry of Health
attribution
Egypt Nahla Attia
[email protected] Ministry of Health Egypt
José Mauricio Bermúdez
El Salvador
[email protected]
Recinos
Equatorial Guinea
Eritrea Michael Ghirmai Haile
[email protected]
Katrin.Tomson- Agency of Medicines of Leading Specialist of
Estonia Katrin Tomson-Johanson
[email protected] Estonia Department of Inspection
Eswatini
Drug Dependency Prevention
Ethiopia Baharu Zewdie Moya
[email protected]
and Control
5
Annex 2
Country Name Focal Point E-mail Affiliation Position
Medicines Regulatory
Authority, Fiji
Pharmaceutical &
Fiji Ilisabeta May Pesamino
[email protected] Chief Pharmacist
Biomedical Services Center,
Fiji Ministry of Health &
Medical Services
Finland Katja Pihlainen
[email protected]
France Aldine Fabreguettes
[email protected]
Senior Specialist,
Gabon Okouyi Ndakissa
[email protected] Department of
Pharmaceutical Activities
Gambia
LEPL Regulation Agency for Head of Drug Inspection
Georgia Nana Shashiashvili
[email protected] Medical and Pharmaceutical Division at the Monitoring
Activities Department
Germany Annette Viktoria Hinze
[email protected]
Germany
[email protected]).
Director, Pharmaceutical
Ghana Martha Gyansa-Lutterodt
[email protected]
Services
Greece Ioanna Siamou
[email protected]
Grenada
Departamento de
Erica Janeth Cohobon Regulacion y control de
Guatemala
[email protected]
Lepe productos farmeuticos y
afines
Guinea
Guinea-Bissau
Guyana
Marie Judith Robuste
Haiti
[email protected] Chef de Service
Roche
6
Annex 2
Country Name Focal Point E-mail Affiliation Position
Instituto Hondureño para la
Alex Virgilio Santos Prevención del Alcoholismo,
Honduras
[email protected] Director General
Moreno Drogadicción y
Farmacodependencia
Hungary Tímea Kahlesz
[email protected]
Iceland Bjarni Sigurðsson
[email protected] Ministry of Health Pharmacist
India Rakesh Chadda
[email protected]
Dra Agusdini Banun
Indonesia
[email protected]
Saptaningsih
Director General of
Iran (Islamic Republic of) Ahmad Hajebi
[email protected] Ministry of Health department for Mental
Health and substance abuse
Iran (Islamic Republic of) Alebouyeh
[email protected]
Iraq Abdulghani
[email protected]
Assistant Principal,
Ireland Brennan
[email protected]
Department of Health
Higher Executive Officer,
Ireland Byran Sheehan
[email protected]
Department of Health
Head of Public Health
Israel Itamar Grotto
[email protected] Ministry of Health
Services
The Component Authority for
Israel Tal Lavy
[email protected] Narcotics, Psychotropics, and
Precursors
Permanent Mission of Israel
Israel
[email protected] Adviser
to the UN, Geneva
Directorate General for
Italy Pietro Canuzzi, MD
[email protected]
Health Prevention
Italy Rocco Signorile
[email protected] Ministry of Health
Jamaica Lishann Salmon
[email protected]
Jamaica Winston De La Haye
[email protected]
7
Annex 2
Country Name Focal Point E-mail Affiliation Position
Jamaica Michelle Walker
[email protected]
Japan
[email protected]
Jordan Heyam Wahbeh
[email protected]
Kazakhstan Prilutskaya Marina
[email protected]
Director Pharmacy and
Kenya Cheworei Sichey
[email protected] Poisons Board Quality
Control Laboratory
Kenya Simon Njuguna
[email protected] Director of Mental Health
Kiribati Biribo Kararaiti
[email protected]
Kuwait Ali Abdulmohsen Jaragh
[email protected]
Kyrgyzstan Kanyshai Damirbek
[email protected]
Khatthanaphone Head of Health Promotion
Lao People’s Democratic Republic
[email protected]
Phandoangsy and Nutrition Unit
Latvia Linda Veisberga
[email protected]
Lebanon Marie-Therese Matar
[email protected]
Lesotho Masello Sello
[email protected]
Liberia
Libya
Head of the Drugs and
Psychotropic Substances
Lithuania Rima Mačiūnienė
[email protected]
Precursors Control and Risk
Assessment Division
Luxembourg Alain Origer
[email protected]
Mahavany Vénot Amélie
Madagascar
[email protected] Pharmacien Inspecteur
Nicole
Assistant Director of
Malawi Michael Udedi
[email protected] Clinical Services (Mental
health and substance abuse)
8
Annex 2
Country Name Focal Point E-mail Affiliation Position
Senior Principal Assistant
Director Licensing Branch
Malaysia Rohaida binti Zakaria
[email protected] Ministry of Health (Controlled SubSection),
Pharmacy Enforcement
Division
Deputy Director General,
Pharmaceuticals; Medicine
Maldives Aishath Mohamed
[email protected]
and Therapeutic Goods
Division
Ministère de la Santé et des
Mali Sékou Oumar Demeble
[email protected] Conseiller Technique
Affaires Sociales
Directeur de la Pharmacie et
Mali Yaya Coulibaly
[email protected]
du Médicament
Malta Victor P. Pace
[email protected]
Marshall Islands Julia Alfred
[email protected] Secretary of Health
Directeur de la pharmacie et
Mauritania Aboubacry amadou BA
[email protected] Ministère de la santé
des laboratoires
Direction de la pharmacie et
chef de service
Mauritania Mohamed lemine Eddine
[email protected] des laboratoires / Ministère de
enregistrement
la santé
Director health Services
Mauritius
[email protected]
(DHS)
Mauritius A. Jhugroo
[email protected] Adviser, Substance Abuse
Verificador- Dictaminador
Mexico David Correa Pina
[email protected]
Especializado
Micronesia (Federated States of) Benido Victor
[email protected]
Monaco Isabelle Kessedjian
[email protected]
Analyst at Division of
Ministry of Health of
Mongolia Amarjargal Choijoo
[email protected] Pharmaceuticals and
Mongolia
Medical Devices
9
Annex 2
Country Name Focal Point E-mail Affiliation Position
Head of the Department for
Montenegro Jasna Sekulic
[email protected] prevention policy of drug
abuse
Morocco Hassan Elkarimi
[email protected]
Directeur, OMDA, CHU
Morocco Jallal Toufiq
[email protected]
Ar-Razi, Salé
Eugénia Guelfrida Salesio
Mozambique
[email protected]
Teodoro
Drug Dependency Treatment
Program
and Research Unit,
Myanmar Nanda Myo Aung Wan
[email protected] Manager/Consultant
Department of Medical
Psychiatrist
Services
Deputy Director(Drugs) /
Myanmar Tin Wah Win
[email protected] Department of Food and
Drug Administration
Namibia Ester Mvula
[email protected]
Nauru Richard Leona
[email protected]
Nepal
Netherlands Liefke Huizinga
[email protected]
New Zealand Emily Kay
[email protected]
New Zealand Lauren Bellamore
[email protected] Ministry of Health Advisor (Drug Intelligence)
Karla Vanessa Delgado
Nicaragua
[email protected]
Martinez
Niger Haoua Na Allah Alou
[email protected]
Nigeria Rafiu Folahan Akanbi
[email protected]
Niue Grizelda Mokoia
[email protected]
North Macedonia
Anne S. Onsgård
Norway
[email protected]
Sagabråten
10
Annex 2
Country Name Focal Point E-mail Affiliation Position
Oman Mahmood Al Abri
[email protected]
Pakistan Institute of Medical
Pakistan Rizwan Taj
[email protected] Head of Psychiatry
Sciences Islamabad
Chief Pharmacist, Chief of
Palau Clarette Matlab
[email protected]
Ancillary Services
Palau
[email protected]
Palau Marla Ito
[email protected]
Mental Health Program
Panama Jose Calderon
[email protected] Ministry of Health
Chief
Papua New Guinea Vicky Wari
[email protected]
Paraguay
Peru Judith Castañeda Alcántara
[email protected]
Department of Health,
Philippines Jose Bienvenido Leabres
[email protected] Program Manager
Philippines
Department of Health,
Philippines Clara Fuderanan
[email protected] Unit Head
Philippines
Department of Health,
Philippines Carol Narra
[email protected] Unit Head
Philippines
National Bureau for Drug
Poland Michał Kidawa
[email protected]
Prevention
General-Directorate for
Intervention on Addictive
Director of Planning and
Portugal Graça Vilar
[email protected] Behaviours and
Intervention Department
Dependencies, Ministry of
Health
Puerto Rico
Qatar Majid Ali Al Abdulla
[email protected]
Republic of Korea Mi Young Hyun
[email protected]
11
Annex 2
Country Name Focal Point E-mail Affiliation Position
Pharmaceutical licensing
Republic of Moldova Cristina Bogos
[email protected] principal specialist
activity
Chairman of the Standing
Medicine and medical devices
Republic of Moldova Oleg Costachi
[email protected] Committee on Drug
agency
Control.
Romania Camelia Bunaciu
[email protected]
Russian Federation Olga Panova
[email protected]
Rwanda
Saint Kitts and Nevis
Saint Lucia Donna Daniel
[email protected]
Programme Officer,
Substance Abuse Unit,
Saint Lucia Paul Caleb
[email protected]
Department of Health and
Wellness
Saint Vincent and the Grenadines
Samoa Robert Thomsen
[email protected]
San Marino Gabriele Rinaldi
[email protected] Health Authority Director
San Marino Andrea Gualtieri
[email protected] Health Authority MD
Sao Tome and Principe
Saudi Food and Drug
Saudi Arabia Adnan Alshammary
[email protected]
Authority
Senegal Bintou Dia
[email protected]
Serbia Nataša Savić
[email protected]
Seychelles
Sierra Leone
12
Annex 2
Country Name Focal Point E-mail Affiliation Position
Senior Executive
Singapore Ong Lay Tin
[email protected] Ministry of Health (International Cooperation)
/ Public Health Group
Department of Drug Strategy
Coordination and Monitoring Coordinator of the Slovak
Slovakia Peter Koren
[email protected]
of Drugs, Ministry of Health EWS, Reitox National FP
of the Slovak Republic
Slovenia Joze Hren
[email protected]
Solomon Islands Paul Orotaloa
[email protected]
Solomon Islands Stephen Araitewa
[email protected]
Somalia
Deputy Director
South Africa MG Molewa
[email protected] Inspectorate & Law
Enforcement
South Sudan
Agencia Española de Jefe de Departamento de
Spain Manuel Ibarra
[email protected] Medicamentos y Productos Inspección y Control de
Sanitarios Medicamento
Agencia Española de Jefe del Área de
Spain Lidia Fernandez Matellano
[email protected] Medicamentos y Productos Estupefacientes y
Sanitarios Psicótropos
Sri Lanka BMW Balasooriya
[email protected]
Sudan
Suriname
Sweden David Lorentzon
[email protected]
Switzerland Diane Steber
[email protected]
Syrian Arab Republic Ahmed Al-Salama
[email protected] Directorate of Mental Health
Tajikistan Salim Abdulazizov
[email protected]
13
Annex 2
Country Name Focal Point E-mail Affiliation Position
Narcotics Control Division
(Standards and Regulations
Pharmacist in Professional
Thailand Chantharakul
[email protected] Sub-Division), Food And
Level
Drug Administration,
Ministry of Public
Narcotics Control Division
(Standards and Regulations
Pharmacist in Professional
Thailand Chavanich
[email protected] Sub-Division), Food And
Level
Drug Administration,
Ministry of Public
Narcotics Control Division,
Food And Drug Director of Narcotics
Thailand Tontisirin
[email protected]
Administration, Ministry of Control Division
Public Health
Official at the Department
National Directorate for
Timor-Leste Soares Henriques
[email protected] of Authorisation and
Pharmacy and Medicine
Markets Introduction
Togo Afèignindou Gnassingbe
[email protected]
Togo
Tonga Melenaite Mahe
[email protected]
Trinidad and Tobago Rohit Doon
[email protected]
Tunisia
Head of Department for
Pharmacovigilance and the
Turkey Demet Aydınkarahaliloğlu
[email protected]
Substances subject to
control
Turkmenistan
Tuvalu
Uganda Hafsa Lukwata
[email protected] Senior Medical Officer
14
Annex 2
Country Name Focal Point E-mail Affiliation Position
Deputy Director of the State
Agency “The Center for
Ukraine Liudmyla Konoshevych
[email protected] Ministry of Health of Ukraine
Mental Health Monitoring
of Drugs and Alcohol”
Head of the Department of
National Strategy and
Policy on the Circulation of
Psychoactive Substances of
Ukraine Viktoria Kurlova
[email protected] Ministry of Health of Ukraine
the State Agency “Center
for Mental Health
Monitoring of Drugs and
Alcohol”
the State Agency “The
Center for Mental Health
Ukraine Sergii Shum
[email protected] Ministry of Health of Ukraine
Monitoring of Drugs and
Alcohol”
United Arab Emirates
United Kingdom of Great Britain
Catherine Crawford
[email protected] Public Health England Head of Focal Point
and Northern Ireland
United Kingdom of Great Britain
Alberto Oteo
[email protected] Public Health England Project manager
and Northern Ireland
United Republic of Tanzania Sara Maongezi
[email protected]
Center for Drug Evaluation & Senior Program Manager
United States of America Jim Hunter
[email protected]
Research Controlled Substances
Area programatica de salud
Uruguay Horacio Porciuncula
[email protected]
mental
Uzbekistan
Vanuatu Jerry Iaruel
[email protected]
Venezuela (Bolivarian Republic of)
15
Annex 2
Country Name Focal Point E-mail Affiliation Position
Head of Prevention
Department, Viet Nam
Viet Nam Mhin Tam Nguyen
[email protected] Ministry of Health
Authority for HIV/AIDS
Control
Yemen
Zambia Nita Besa
[email protected]
Head of department mental Deputy Director Mental
Zimbabwe Sacrifice Chirisa
[email protected]
Health Services Head office Health
= = =
16
Saatja: <
[email protected]>
Saadetud: 14.06.2021 10:00
Koopia: <
[email protected]>
Teema: WHO: C.L.20.2021 (44th ECDD)
Dear Member States of the World Health Organization,Please find attached,
in the six official languages, C.L.20.2021 regarding the 44th Expert
Committee on Drug Dependence (ECDD) which will meet from 11 to 15 October
2021.Should you have questions regarding C.L.20.2021 please send an email
to
[email protected] regards,Department of Governing
BodiesWorld Health Organization